Endra Life Sciences
NDRA
Endra Life Sciences (NDRA) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$2.10
- EPS estimate
- −$1.95
- EPS surprise
- −7.69%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 14, 2025 | −$1.95 | −$2.10 | −7.69% | $0.00 | SEC |
| Q2 2025 | Aug 14, 2025 | −$2.27 | −$1.71 | +24.67% | $0.00 | SEC |
| Q1 2025 | May 15, 2025 | −$3.91 | −$1.86 | +52.43% | $0.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$4.10 | −$47.06 | −1047.80% | $0.00 | SEC |
| Q3 2024 | Nov 15, 2024 | −$62.30 | −$9.54 | +84.69% | $0.00 | SEC |
| Q2 2024 | Aug 14, 2024 | −$122.50 | −$140.00 | −14.29% | $0.00 | SEC |
| Q1 2024 | May 14, 2024 | −$472.50 | −$455.00 | +3.70% | $0.00 | SEC |
| Q4 2023 | Mar 28, 2024 | −$630.00 | −$297.50 | +52.78% | $0.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$752.50 | −$700.00 | +6.98% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$962.50 | −$752.50 | +21.82% | $0.00 | SEC |
| Q1 2023 | May 15, 2023 | −$1,828.75 | −$1,627.50 | +11.00% | $0.00 | SEC |
| Q4 2022 | Mar 14, 2023 | −$1,575.00 | −$1,820.00 | −15.56% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$1,925.00 | −$1,750.00 | +9.09% | $0.00 | — |
| Q2 2022 | Aug 15, 2022 | −$1,925.00 | −$2,100.00 | −9.09% | $0.00 | — |
| Q1 2022 | May 12, 2022 | −$2,625.00 | −$2,450.00 | +6.67% | $0.00 | — |
| Q4 2021 | Mar 30, 2022 | −$2,800.00 | −$2,450.00 | +12.50% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$2,800.00 | −$2,100.00 | +25.00% | $0.00 | — |
| Q2 2021 | Aug 12, 2021 | −$2,450.00 | −$2,800.00 | −14.29% | $0.00 | — |
| Q1 2021 | May 17, 2021 | −$2,625.00 | −$2,100.00 | +20.00% | $0.00 | — |
| Q4 2020 | Mar 25, 2021 | −$5,075.00 | −$3,500.00 | +31.03% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Endra Life Sciences (NDRA) last report earnings?
Endra Life Sciences last reported on Nov 14, 2025, covering fiscal Q3 2025.
Did NDRA beat earnings estimates?
No. Endra Life Sciences reported EPS of −$2.10 for Q3 2025 against a −$1.95 estimate — a 7.69% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.